Shanxi Zhendong Pharmaceutical Co Ltd

Shanxi Zhendong Pharmaceutical Co Ltd has a market price of 5.6 CNY per share, resulting in a market capitalization of 5.56 billion CNY. The company's price-to-book ratio is 1.66, and its price-to-tangible-book ratio is also 1.66, indicating that the market values the company slightly above its book value. The enterprise value to EBITDA ratio is negative at -22.15, reflecting the company's current operating losses. The enterprise value to revenue ratio is 2.11, suggesting that the company is valued at 2.11 times its annual revenue. The company's profitability metrics are concerning. The return on equity is -8.99%, and the return on assets is -6.51%, both significantly below the industry median for pharmaceutical companies. The company reported a net loss of 301.06 million CNY and an operating loss of 264.94 million CNY in the latest period. These figures indicate a deteriorating financial performance compared to the industry's preferred metrics of positive and stable returns. Geographically, the company's revenue is concentrated in the domestic Chinese market, with no significant international exposure disclosed. The company's revenue concentration is high, with no diversification across multiple regions or markets. This concentration increases the company's vulnerability to domestic economic and regulatory changes. The company's growth trajectory is negative. Revenue for the latest period was 2.78 billion CNY, which is below the analyst estimate of 3.73 billion CNY. The company is expected to report a decline in revenue in the current fiscal year, with no clear signs of recovery in the next fiscal year. The operating cash flow is negative at -460.48 million CNY, and the free cash flow is also negative at -367.74 million CNY, indicating a lack of liquidity and financial flexibility. The company's risk profile is moderate. The liquidity risk is rated as medium, with a current ratio of 2.1, suggesting that the company has sufficient current assets to cover its current liabilities. However, the company has a negative net cash position after subtracting total debt, which increases its liquidity risk. The dilution risk is rated as low, with no significant dilution potential in the near term. The company's debt-to-equity ratio is 0.09, indicating a relatively low level of leverage. Recent events and disclosures indicate that the company is facing financial challenges. The company reported a net loss and an operating loss in the latest period, which is a significant concern for investors. The company's capital expenditure was -179.12 million CNY, indicating a reduction in investment in new projects or facilities. The company's shares outstanding are 992.30 million, with no dilution in the diluted shares outstanding.